Securities code: 002252 securities abbreviation: Shanghai Raas Blood Products Co.Ltd(002252) Announcement No.: 2022-008 Shanghai Raas Blood Products Co.Ltd(002252)
Announcement of the resolution of the first extraordinary general meeting of shareholders in 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special tips:
1. There is no case of adding, changing or rejecting proposals at this shareholders’ meeting;
2. This general meeting of shareholders does not involve changing the resolutions adopted by previous general meetings of shareholders;
1、 Convening and attendance of the meeting
(I) convening of the meeting
1. The on-site meeting will be held at 13:00 on Monday, February 14, 2022;
Online voting time: Monday, February 14, 2022;
Among them, the specific time of online voting through the trading system of Shenzhen stock exchange is: trading time on February 14, 2022, i.e. 9:15-9:25, 9:30-11:30, 13:00-15:00; The specific time of voting through the Internet voting system of Shenzhen stock exchange is any time from 9:15 to 15:00 on February 14, 2022.
2. Venue of the on-site meeting: Nanjiao Hotel, No. 398, Zhanyuan Road, Nanqiao new town, Fengxian District, Shanghai;
3. Convening method: the combination of on-site open voting and online voting;
4. Convener: the 5th board of directors of the company
5. Moderator: Mr. Chen Jie, chairman and general manager
6. The convening and convening procedures of this general meeting of shareholders comply with relevant laws, administrative regulations, departmental rules, normative documents and the relevant provisions of the articles of Association;
(II) attendance at the meeting
1. General attendance of shareholders
49 shareholders and their authorized representatives attended the meeting through on-site and online voting, representing 3103991072 shares, accounting for 46.0479% of the total voting shares of the company.
Among them, 9 shareholders and their authorized representatives attended the on-site meeting, representing 3023565629 shares, accounting for 44.8548% of the total voting shares of the company;
40 shareholders attended the meeting through online voting, with 80425443 representative shares, accounting for 1.1931% of the total voting shares of the company.
2. Attendance of minority shareholders
A total of 44 minority shareholders (except directors, supervisors, senior managers and other shareholders who individually or jointly hold more than 5% of the company’s shares) and shareholders’ authorized representatives attended the meeting through on-site and online voting, representing 85036076 shares, accounting for 1.2615% of the total voting shares of the company. Among them, 4 minority shareholders and authorized representatives of shareholders attended the meeting, representing 4610633 shares, accounting for 0.0684% of the total voting shares of the company;
40 minority shareholders attended the meeting through online voting, with 80425443 representative shares, accounting for 1.1931% of the total voting shares of the company.
3. Some directors, supervisors and Secretary of the board of directors of the company attended the shareholders’ meeting, and senior managers attended the meeting as nonvoting delegates. Lawyers from Beijing Guofeng law firm attended the meeting, witnessed it and issued legal opinions.
2、 Deliberation and voting of proposals
The general meeting of shareholders adopts the combination of on-site voting and online voting. The voting results are as follows:
1. The proposal on by election of independent directors of the company was deliberated and adopted
The overall voting is as follows:
3103330672 shares agreed, accounting for 99.9787% of the total number of valid voting shares held by shareholders attending the meeting; 646600 dissenting shares, accounting for 0.0208% of the total number of valid voting shares held by shareholders attending the meeting;
13800 shares abstained, accounting for 0.0004% of the total number of valid voting shares held by shareholders attending the meeting;
Among them, the voting situation of minority shareholders (other than directors, supervisors, senior managers and shareholders who individually or jointly hold more than 5% of the shares of the company) is as follows:
84375676 shares were approved, accounting for 99.2234% of the total number of valid voting shares held by minority shareholders attending the meeting; Against 646600 shares, accounting for 0.7604% of the total number of valid voting shares held by minority shareholders attending the meeting; 13800 shares were abstained, accounting for 0.0162% of the total number of valid voting shares held by minority shareholders attending the meeting.
3、 Legal opinions issued by lawyers
1. Law firm: Beijing Guofeng law firm
2. Witness lawyers: Meng Wenxiang, Liu Liang
3. Concluding comments: the qualification of the convener of this general meeting of shareholders of the company is legal and effective, and the convening, convening procedures and announcement of this general meeting of shareholders comply with the relevant provisions of laws, regulations and the articles of Association; The qualification of the participants is legal and valid; The voting procedures and results comply with the provisions of laws, regulations and the articles of Association; The relevant resolutions adopted at this shareholders’ meeting are legal and valid.
4、 Documents for future reference
1. Resolutions of the company’s first extraordinary general meeting in 2022;
2. Legal opinion of Beijing Guofeng law firm on the first extraordinary general meeting of shareholders in Shanghai Raas Blood Products Co.Ltd(002252) 2022.
It is hereby announced.
Shanghai Raas Blood Products Co.Ltd(002252)
February 15, 2002
